Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Inflammaging-Associated Cytokine Signaling to Improve Efficacy and Reduce Immune-Related Toxicities of Anti-PD-1/CTLA-4 Therapy

NCT07838974 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT07838974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07838974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Inflammaging-Associated Cytokine Signaling to Improve Efficacy and Reduce Immune-Related Toxicities of Anti-PD-1/CTLA-4 Therapy
Lead sponsor
University of Southern California
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 1, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma